Greg Yothers, PhD

Research Professor, Biostatistics

Senior Deputy Director and Deputy Group Statistician, NRG Oncology SDMC

Contact

201 N Craig St, Suite 350, NRG Oncology SDMC
R-znvy: tnlfg8@cvgg.rqh
Primary Phone: 967-838-8289
Fax: 967-838-6832
Web site:

Assistant(s): 
Patricia Cole, pbyr@afnoc.cvgg.rqh, 967-838-6404

Personal Statement

My primary research interest is the design, implementation and analysis of phase II and III clinical trials for cancer research.  My work with the NRG Oncology clinical trials group has included trials evaluating therapies for the treatment of colon, rectal, and breast cancer.  The focus of my methodological research has been the development of statistical methodologies for identifying a subset of a clinical trial population where a treatment is effective.

 I am one of the Primary Investigators for the NRG Oncology Statistics
and Data Management Center (SDMC) - a clinical trials research group comprising
200+ employees.  I am the Senior Deputy Director and Deputy Group Statistician for NRG
Oncology SDMC.


Education

2003 | University of Pittsburgh, Pittsburgh, PA | Doctor of Philosophy in Statistics

1998 | University of Pittsburgh, Pittsburgh, PA | Master of Arts in Statistics
1981 | Pennsylvania State University, State College, PA | Bachelor of Science in Mathematics


Selected Publications

Cohen R, Vernerey D, Bellera C, Meurisse A, Henriques J, Paoletti X, Rousseau B, Alberts S, Aparicio T, Boukovinas I, Gill S, Goldberg RM, Grothey A, Hamaguchi T, Iveson T, Kerr R, Labianca R, Lonardi S, Meyerhardt J, Paul J, Punt CJA, Saltz L, Saunders MP, Schmoll HJ, Shah M, Sobrero A, Souglakos I, Taieb J, Takashima A, Wagner AD, Ychou M, Bonnetain F, Gourgou S, Yoshino T, Yothers G, de Gramont A, Shi Q, AndrĂ© T. Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. Eur J Cancer. 2020 May;130:63-71. doi: 10.1016/j.ejca.2020.02.009. Epub 2020 Mar 12. PubMed PMID: 32172199.

 

Salem ME, Yin J, Goldberg RM, Pederson LD, Wolmark N, Alberts SR, Taieb J, Marshall JL, Lonardi S, Yoshino T, Kerr RS, Yothers G, Grothey A, Andre T, De Gramont A, Shi Q. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol. 2020 Apr;31(4):480-486. doi: 10.1016/j.annonc.2019.12.007. Epub 2020 Jan 16. PubMed PMID: 32085892.

 

Gresham G, Diniz MA, Razaee ZS, Luu M, Kim S, Hays RD, Piantadosi S, Tighiouart M, Yothers G, Ganz PA, Rogatko A. Evaluating Treatment Tolerability in Cancer Clinical Trials using the Toxicity Index. J Natl Cancer Inst. 2020 Feb 24;. doi: 10.1093/jnci/djaa028. [Epub ahead of print] PubMed PMID: 32091598.

 

Link to Greg Yothers complete bibliography...

Greg  Yothers